What ChondroFiller is and how it works in the hip joint

ChondroFiller® liquid — also known as Liquid Cartilage™ — is an injectable collagen scaffold designed to give a damaged hip joint something it cannot produce on its own: a biological framework that the body's own repair cells can move into and build upon.

The material itself is a purified Type I collagen gel derived from murine sources. Once placed inside the hip joint it sets in situ, conforming to the shape of the cartilage defect and bonding to the surrounding tissue. It contains no living cells. Instead, the scaffold works by a process called acellular matrix-induced chondrogenesis — in plain terms, it sends chemical signals that attract progenitor cells from the synovial lining and underlying bone, drawing them into the collagen structure where they can mature and support cartilage repair over time. The device is CE-marked as a Class III medical implant, reflecting its classification as an active biological scaffold rather than a simple filler or lubricant.

Within the Lincolnshire Hip service pathway, ChondroFiller is offered as an ultrasound-guided outpatient injection for patients with suitable focal hip cartilage defects — a clinic appointment, not a surgical admission. The goal is to support the body's own repair processes at the defect site before damage has progressed beyond the point where preservation remains viable.

Hip-specific clinical evidence: what the published data actually show

The most substantial published evidence for ChondroFiller in the hip comes from a prospective cohort study published in the Journal of Hip Preservation Surgery (2021) by the Jerosch group. Twenty-six adults with femoroacetabular impingement (FAI) and acetabular cartilage lesions larger than 2 cm² were treated arthroscopically and followed for between 12 and 60 months. Of the 21 patients evaluable at final follow-up, 17 — 81% — achieved good or excellent MRI-verified cartilage healing outcomes. Mean Harris Hip Score improved by approximately 33 points, a clinically meaningful gain.

The most actionable finding from that study concerns patient selection. Those with Tönnis grade 2–3 hip osteoarthritis — where joint-space narrowing is already established — fared poorly, and two of the 26 participants subsequently required total hip replacement. This is the clearest clinical boundary the published hip data provide: ChondroFiller appears suited to focal defects in joints that retain reasonable overall health, not to hips with advanced, diffuse wear.

Mechanistic support for the hip comes from two further sources. A 2025 ex vivo study using human osteochondral explants found that ChondroFiller scaffolds produced a 2.4-fold increase in DNA content by day 14, confirming that host cell recruitment into the collagen matrix does occur — independent of joint site. A 2025 case report documented complete pain relief and restored function in a 32-year-old man following ChondroFiller treatment of a 15×5 mm femoral head dome defect, without the need for microfracture.

Taken together, this body of evidence is promising but should be understood for what it is: one prospective cohort, not a randomised controlled trial.

Where the broader evidence base reaches and where it stops

The broader body of ChondroFiller data — drawn from multiple independent European cohorts and a small randomised trial — consistently shows patient-reported outcome scores improving by around 30 points, alongside MRI MOCART scores in the range of 81–84. A MOCART score above 80 means the repair tissue has filled most of the defect cavity and is integrating well with the surrounding native cartilage — a structural benchmark that helps explain why functional gains appear durable in published follow-up periods of up to three years.

These data carry two important implications for hip patients. First, they validate the scaffold's mechanism and safety profile across a substantial published dataset: more than 19,000 cases have been documented globally, with no serious device-related adverse events identified in peer-reviewed reports. Second, they form the primary foundation of ChondroFiller's CE Class III classification. The hip cohort described in the previous section is supplementary evidence within that regulatory framework, not its central pillar — an important structural fact for anyone comparing the breadth of data behind the device with the narrower base of hip-specific outcomes.

On the imaging side, the gap is plain. No published study has applied standardised MRI outcome scoring to hip ChondroFiller results — neither MOCART nor any equivalent measure. The MERCH score, developed in 2023 through a formal expert consensus process and designed specifically for post-operative hip cartilage assessment, only underscores the point: hip cartilage science is still constructing the measurement tools that research in other joints has used for years. That is not a reason for alarm — it is an honest description of where a maturing field currently stands. The mechanistic and safety evidence transfers; what cannot yet be said with confidence is whether the magnitude of functional improvement seen elsewhere is replicated precisely in the hip.

Which hip patients are most likely to benefit

Translating the published findings into a practical self-check begins with two questions: how focal is the damage, and how far has joint wear progressed?

The best-evidenced indication is an isolated acetabular cartilage defect larger than 2 cm² occurring in the setting of femoroacetabular impingement, in a hip that retains reasonable overall joint health. The Tönnis grading system offers a simple map of that progression — grade 0 to 1 indicates minor or absent degenerative change; grade 2 to 3 reflects established joint-space narrowing and more advanced osteoarthritis. As the evidence presented above shows, patients at Tönnis grade 2–3 fared poorly in the primary hip cohort, with some requiring total hip replacement — making OA stage arguably as important as defect size when considering candidacy.

Age alone is not a formal cut-off, but real-world data add useful context. An analysis of 116,179 hip cartilage repair procedures performed in Germany between 2006 and 2022 found that regenerative and scaffold-based procedures are concentrated in patients with a mean age of 27.73 years. That is a population anchor, not a ceiling.

The biological argument for early assessment is straightforward: hip articular cartilage is avascular, meaning it has no direct blood supply and very limited capacity to heal itself. A 2022 registry study of 422 patients confirmed that acetabular cartilage damage of any grade — even low-grade lesions — independently worsens outcomes after hip arthroscopy. Waiting is not a neutral choice when the tissue concerned cannot meaningfully repair on its own.

The hip's biomechanical demands and what they mean for recovery

Cartilage repair in the hip takes place in one of the most mechanically demanding environments in the body. The hip joint routinely transmits forces several times body weight during walking, stair-climbing, and rising from a chair — loads distributed across the acetabular cartilage in every step of daily life.

A 2024 in-vitro biomechanical study found that the ChondroFiller collagen gel, in its early phase before cells have migrated into the scaffold and begun integration, does not protect the opposing cartilage surface from mechanical damage under cyclic loading. The authors' practical conclusion is direct: full weight-bearing should be delayed until stable defect filling is established. This is a clinically grounded protocol, not precautionary guesswork — the scaffold needs time to recruit host cells before it can handle the joint's normal demands.

The concave, constrained geometry of the acetabulum adds a further layer of complexity. Unlike more accessible joint surfaces, the cup-shaped acetabulum leaves less margin for early mechanical disturbance during the critical integration window.

A structured, hip-specific rehabilitation plan — phasing weight-bearing and activity resumption in line with expected scaffold maturation — is therefore a core part of appropriate clinical management. Patients can reasonably expect clear guidance on this timeline from their treating consultant before discharge.

Honest gaps and questions worth raising at consultation

Four gaps in the evidence are worth holding in mind before any consultation: no randomised controlled trial has been completed for ChondroFiller in the hip; the 81% good/excellent result derives from 21 evaluable patients at final follow-up; no outcome data extend beyond five years for hip-treated patients; and no published head-to-head trial has compared ChondroFiller directly with AMIC, BMAC, or microfracture in the hip joint. These limits have been covered in earlier sections — they are restated here only to turn them into questions worth raising in the room.

• What is my Tönnis grade, and does it fall within the evidence-supported range? The primary cohort showed poor results at grades 2–3; OA stage is arguably as important as defect size.
• Is the lesion's size and anatomical location appropriate for this approach? The published data cover acetabular defects larger than 2 cm² and, more recently, focal femoral head dome lesions — not all positions are equivalent.
• What is the planned weight-bearing and rehabilitation protocol, and at what point will loading begin? A phased timeline is clinically grounded given what is known about early scaffold stability.
• What realistic alternatives exist, and why is this approach preferred over them? Understanding the comparators helps anchor the decision.

Good answers to these questions — not reassurances, but honest clinical reasoning — are a fair expectation of any specialist appointment. They are also the surest way to judge whether the evidence, limited as it is, applies to your specific hip. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment; a consultation is the point at which the published data become personal.

1. [1] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing — knee focal cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Arthroscopic utilisation of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Trends in Cartilage Repair Techniques for Chondral Defects in the Hip in Germany 2006–2022. (2024). https://doi.org/10.3390/life14101262 https://doi.org/10.3390/life14101262
6. [6] Microfracture of Acetabular Chondral Lesions is Not Superior to Other Cartilage Repair Techniques in Patients with Femoroacetabular Impingement: Systematic Review. (2023). https://doi.org/10.1016/j.arthro.2023.05.034 https://doi.org/10.1016/j.arthro.2023.05.034
7. [7] Acetabular cartilage lesions predict inferior mid-term outcomes for arthroscopic labral repair and treatment of FAI. (2022). https://doi.org/10.1016/j.arthro.2022.05.013 https://doi.org/10.1016/j.arthro.2022.05.013